Reality Check on Ulcerative Colitis
Market access for ulcerative colitis treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 66% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In May 2021, the FDA gave an additional indication to Bristol Myers Squibb's Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis. It is the first and only sphingosine 1-phosphate (S1P) receptor modulator approved for this indication
- Key Findings: New-to-market products should expect stiff competition due to the number of originator biologics and biosimilars currently available and more expected in the pipeline
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.